Advancing TransCon CNP: Navigating Achondroplasia Treatment Progress

This keynote will provide an in-depth review of the TransCon CNP program, emphasizing its role in addressing achondroplasia. It will cover Ascendis Pharma's achievements, the significance of innovative treatments like navepegritide, and updates on regulatory progress and clinical findings. Strategically, the talk will discuss the brand development of Yuviwel, planned combination therapies, and global collaborations, concluding with key takeaways, future goals for market leadership, and a call...